People Science, a direct-to-consumer scientific research company that provides a scaled research and development (R&D) platform for alternative medicines, announced today a $5.3 million seed round led by Acre Venture Partners, with participation from Bluestein Ventures, THIA Ventures, and FORM Life Ventures. The previous seed round was supported by Noetic Fund, Woven Science, and LifeForce Capital, bringing their total seed funding to $8.5M.
The new funding will be used to support the company’s expansion into nutrition and food as medicine, in addition to their current research efforts on natural and synthetic psychedelics, the microbiome, cannabis and cannabinoid medicines, and digital health interventions. Acre Venture Partners Co-Founder and Managing Partner Lucas Mann will join the People Science Board of Directors.
Through its technology platform, CHLOE, People Science is constructing a new clinical research infrastructure for alternative medicines that connects people, doctors, and scientists (the Consumer Health Learning and Organizing Ecosystem). CHLOE is a software platform that combines a consumer-facing mobile app with a rigorous high-quality clinical research platform.
CHLOE can help consumers understand which alternative medicines work best for them. Companies and other researchers work with People Science directly or through licensing CHLOE to test their ideas and products. Sponsored clinical studies with CHLOE began in late 2022, with the app expected to be available to the public in early 2023.
People Science will also use the latest round of funding to continue developing the CHLOE technology platform to support additional consumer-facing features as well as to support their growing client pipeline for CHLOE software licensing. To support customer growth and retention, the core team will grow.
